BMS ends 2010 with new pearl on its string, promise for more US approvals
This article was originally published in Scrip
On the heels of winning an additional six months of US marketing exclusivity protection for its blockbuster heart attack and stroke prevention drug Plavix (clopidogrel bisulfate), Bristol-Myers Squibb delivered a better-than-expected 2010 fourth-quarter earnings report, although sales of Plavix saw only a modest 6% increase from $1.6 billion to $1.7 billion.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.